Showing results (761-770 of 857) with videos related to

Sort By:
Pageof 86
Kidney International Reports|February 2, 2026
Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous NephropathyMatias Trillini, Valentina Portalupi, Alessia Gennarini, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2014
Building a network of ADPKD reference centres across Europe: the EuroCYST initiativeKatja Petzold, Ron T Gansevoort, Albert C M Ong, et al.
Diabetes, Obesity & Metabolism|December 27, 2016
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathyMichelle J Pena, Dick de Zeeuw, Dennis Andress, et al.
Kidney International|February 5, 2015
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesChristoph Licht, Larry A Greenbaum, Petra Muus, et al.
Human Mutation|November 8, 2006
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural modelsRebecca E Saunders, Cynthia Abarrategui-Garrido, Véronique Frémeaux-Bacchi, et al.
Lancet (London, England)|August 27, 2013
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trialAnna Caroli, Norberto Perico, Annalisa Perna, et al.
Kidney International Reports|April 24, 2026
Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous NephropathyMatias Trillini, Federica Casiraghi, Alessia Gennarini, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2019
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized TrialBarbara Ruggiero, Matias Trillini, Lida Tartaglione, et al.
Italian Journal of Pediatrics|September 15, 2020
Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases networkMarco Salvatore, Agata Polizzi, Maria Chiara De Stefano, et al.
The Lancet. Diabetes & Endocrinology|November 7, 2017
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trialAneliya Parvanova, Matias Trillini, Manuel A Podestà, et al.
Pageof 86